FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s supplemental Biologics License Application (sBLA) for Gazyva® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive Phase III MAJESTY results, which show superiority of Gazyva over an immunosuppressive therapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s supplemental Biologics License Application (sBLA) for Gazyva® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive Phase III MAJESTY results, which show superiority of Gazyva over an immunosuppressive therapy